Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon.

摘要: Idiotypes are distinct clonal markers for B-cell lymphomas. Previously we reported the use of anti-idiotype antibodies in therapy patients with malignancies. Because synergy was demonstrated addition alpha interferon to a murine lymphoma model, performed clinical trial combining these two agents. Here provide an update original anti- idiotype alone and report outcome new combination trial. In 16 treatment courses there were seven partial responses one complete response. 12 antibody responses. Substantial tumor regressions occurred minimal toxicity both trials even refractory conventional chemotherapy. Tumor specimens obtained at time disease progression often contained preponderance idiotype-negative cells, suggesting that exerted strong antitumor effect against antigen-positive cells. Anti-idiotype have reproducible objective activity lymphoma. The may improve initial rate response this treatment. Strategies deal effectively cells should extent duration